Safety Study for Future Treatment of Psoriasis Clinical Trial
Official title:
A Phase I, Double Blind, Randomized, Placebo Controlled, Maximal Dose Study to Determine the Safety, Tolerability of Topical Cream Containing MGC (Medical Grade Cannabis) in Healthy Volunteers
| Verified date | January 2019 |
| Source | One World Cannabis Ltd. |
| Contact | n/a |
| Is FDA regulated | No |
| Health authority | |
| Study type | Interventional |
This single center, prospective, double-blind, placebo-controlled, randomized two parts study (part I and part II) will assess the safety of topical cream (3% CBD and 3% THC), applied twice daily (bid), in healthy subjects, for up to 6 treatment weeks and additional 2 follow-up weeks.
| Status | Completed |
| Enrollment | 26 |
| Est. completion date | January 25, 2019 |
| Est. primary completion date | January 25, 2019 |
| Accepts healthy volunteers | Accepts Healthy Volunteers |
| Gender | All |
| Age group | 18 Years to 60 Years |
| Eligibility |
Inclusion Criteria: - Alanine aminotransferase (ALT), alkaline phosphatase and bilirubin <=1.5xupper limit of normal (ULN) (isolated bilirubin >1.5xULN is acceptable if bilirubin is fractionated and direct bilirubin <35%). - Healthy as determined by a responsible and experienced physician, based on a medical evaluation including medical history, physical examination, laboratory tests and electrocardiogram (ECGs). - A subject with a clinical abnormality or laboratory parameters outside the reference range for the population being studied may be included only if the Investigator and the OWC Medical Monitor agree that the finding is unlikely to introduce additional risk factors and will not interfere with the study procedures. - Subjects with hemoglobin (Hb) values higher than ULN the normal range should always be excluded from enrollment. - A female subject is eligible to participate if she is of non-childbearing potential (postmenopausal or pre-menopausal females with a documented tubal ligation or hysterectomy). Females on hormone replacement therapy (HRT) and whose menopausal status is in doubt will be required to use one of the contraception methods in the protocol. - Male subjects with female partners of child-bearing potential must agree to use one of the contraception methods listed in the protocol. - Agree not to participate in any other interventional clinical trials during the study - Agree to follow study instructions meticulously Exclusion Criteria: - A positive pre-study Hepatitis B surface antigen or positive Hepatitis C antibody result within 3 months of screening. - Current or chronic history of liver disease, or known hepatic or biliary abnormalities (with the exception of Gilbert's syndrome or asymptomatic gallstones). - Have evidence of significant, uncontrolled hematological, endocrine, cerebrovascular, cardiovascular, coronary, pulmonary, gastrointestinal, or neurological disease. (Participants with hypothyroidism who are on adequate and stable thyroid replacement will not be excluded). - History of malignancy within 5 years of Screening or those with a strong family history of cancer (e.g., familial cancer disorders), with the exception of squamous cell or basal cell carcinoma of the skin that has been definitively treated. - A history of drug or alcohol abuse, or a history of regular alcohol consumption within 6 months of the study defined as an average weekly intake of >14 drinks for males or >7 drinks for females. One drink is equivalent to 12 gram of alcohol: 12 ounces (360 mililiter [mL]) of beer, 5 ounces (150 mL) of wine or 1.5 ounces (45 mL) of 80 proof distilled spirits. - Consumption of: Barbiturates, Cocaine, Ethanol, SSRI's, Protease inhibitors, Warfarin, Sildenafil, Theophilline, Tricyclic antidepressants - A positive test for human immunodeficiency virus (HIV) antibody. - The subject has participated in a clinical trial and has received an investigational product within the following time period prior to the first dosing day in the current study: 30 days, 5 half-lives (whichever is longer). - Unable to refrain from the use of prescription or non-prescription drugs, including vitamins, herbal and dietary supplements within 7 days (or 14 days if the drug is a potential enzyme inducer) or 5 half-lives (whichever is longer) prior to the first dose of study medication, unless in the opinion of the Investigator and OWC Medical Monitor the medication will not interfere with the study procedures or compromise subject safety. - History of sensitivity to any of the study medications, or components thereof or a history of drug or other allergy that, in the opinion of the investigator or OWC Medical Monitor, contraindicates their participation. - Pregnant females as determined by positive urine human chorionic gonadotropin test at screening or prior to dosing. - Are pregnant or nursing, or of child bearing potential and not practicing an effective means of birth control. - Are not able to give adequate informed consent. - Have any current problem or a history of substance abuse which, in the opinion of the investigator, might interfere with participation in the protocol. - Have used marijuana within a month of starting the study. - Fail the initial urine drug screen and blood test which tests for illicit drug use within the prior month. |
| Country | Name | City | State |
|---|---|---|---|
| Israel | Sheba Medical Center | Ramat Gan |
| Lead Sponsor | Collaborator |
|---|---|
| One World Cannabis Ltd. |
Israel,
| Type | Measure | Description | Time frame | Safety issue |
|---|---|---|---|---|
| Primary | Incidence rate of AEs/ SAEs | Collection of Adverse events and Serious Adverse Events | 24 hours | |
| Primary | Incidence rate of AEs/ SAEs | Collection of Adverse events and Serious Adverse Events | 6 weeks | |
| Secondary | Specific AEs/ SAEs | Erythema Edema Swelling Itching Heat Pain Cellulitis Other | Baseline to 24 hours | |
| Secondary | Specific AEs/ SAEs | Erythema Edema Swelling Itching Heat Pain Cellulitis Other | baseline to 6 weeks |